Arcus Biosciences (NYSE:RCUS) Price Target Raised to $49.00

Arcus Biosciences (NYSE:RCUS) had its price target upped by Wedbush from $43.00 to $49.00 in a report released on Wednesday morning,Benzinga reports. The brokerage currently has an outperform rating on the stock.

A number of other equities analysts also recently commented on RCUS. Wells Fargo & Company raised their price objective on Arcus Biosciences from $23.00 to $26.00 and gave the stock an “equal weight” rating in a report on Thursday, August 6th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Arcus Biosciences in a report on Thursday, October 15th. Truist Financial reiterated a “buy” rating and set a $40.00 target price (up from $35.00) on shares of Arcus Biosciences in a report on Tuesday, September 8th. TD Cowen began coverage on shares of Arcus Biosciences in a research report on Wednesday, September 16th. They set a “buy” rating for the company. Finally, Citigroup raised their price target on shares of Arcus Biosciences from $45.00 to $50.00 and gave the company a “buy” rating in a report on Wednesday. Twelve equities research analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, Arcus Biosciences currently has an average rating of “Moderate Buy” and a consensus target price of $39.64.

Arcus Biosciences Price Performance

RCUS opened at $18.54 on Wednesday. The company’s 50 day simple moving average is $26.12 and its 200 day simple moving average is $26.14. The company has a debt-to-equity ratio of 0.22, a quick ratio of 3.82 and a current ratio of 3.82. Arcus Biosciences has a 1 year low of $16.87 and a 1 year high of $31.74. The stock has a market capitalization of $2.36 billion, a PE ratio of -4.75 and a beta of 0.94.

Arcus Biosciences (NYSE:RCUS) last posted its quarterly earnings results on Wednesday, August 5th. The company reported ($0.72) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.89) by $0.17. The firm had revenue of $41.00 million during the quarter, compared to the consensus estimate of $21.98 million. Arcus Biosciences had a negative return on equity of 89.54% and a negative net margin of 393.16%. The business’s revenue for the quarter was down 74.4% on a year-over-year basis. As a group, sell-side analysts expect that Arcus Biosciences will post -3.55 EPS for the current year.

Insider Buying and Selling

In other Arcus Biosciences news, CAO Alexander Azoy sold 2,827 shares of the business’s stock in a transaction dated Friday, August 21st. The stock was sold at an average price of $30.00, for a total transaction of $84,810.00. Following the transaction, the chief accounting officer owned 39,581 shares in the company, valued at $1,187,430. The trade was a 6.67% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 7.60% of the stock is owned by company insiders.

Institutional Investors Weigh In On Arcus Biosciences

A number of large investors have recently modified their holdings of RCUS. Sterling Capital Management LLC raised its stake in shares of Arcus Biosciences by 328.4% during the third quarter. Sterling Capital Management LLC now owns 2,716 shares of the company’s stock valued at $70,000 after purchasing an additional 2,082 shares during the period. GAMMA Investing LLC lifted its position in shares of Arcus Biosciences by 22.4% during the third quarter. GAMMA Investing LLC now owns 4,855 shares of the company’s stock worth $125,000 after purchasing an additional 889 shares in the last quarter. WINTON GROUP Ltd boosted its stake in shares of Arcus Biosciences by 59.7% in the second quarter. WINTON GROUP Ltd now owns 52,398 shares of the company’s stock valued at $1,615,000 after purchasing an additional 19,578 shares during the period. Integrated Wealth Concepts LLC purchased a new position in shares of Arcus Biosciences in the second quarter valued at $30,000. Finally, Arizona State Retirement System boosted its stake in shares of Arcus Biosciences by 1.7% in the second quarter. Arizona State Retirement System now owns 24,211 shares of the company’s stock valued at $746,000 after purchasing an additional 409 shares during the period. Institutional investors and hedge funds own 92.89% of the company’s stock.

Key Stories Impacting Arcus Biosciences

Here are the key news stories impacting Arcus Biosciences this week:

• Positive Sentiment: Analyst support: Truist Financial and Wedbush both forecast strong price appreciation for RCUS, suggesting analysts see upside following the recent selloff. Truist Financial Forecasts Strong Price Appreciation for Arcus Biosciences Wedbush Forecasts Strong Price Appreciation for Arcus Biosciences
• Positive Sentiment: Promising casdatifan data: Arcus presented new ARC-20 data evaluating casdatifan across multiple lines of therapy in kidney cancer. The results may support the drug’s development and commercial potential, though investors are likely seeking additional details on efficacy and durability. Arcus Presents New Casdatifan Data
• Neutral Sentiment: Improved liquidity: Arcus estimates it held approximately $694 million in cash, cash equivalents and marketable securities as of September 30, 2026. Proceeds from the offering should further extend its funding runway for clinical development, but the benefit comes with shareholder dilution. Arcus Estimates Cash Position
• Negative Sentiment: Equity dilution: Arcus priced an underwritten public offering of 14.29 million shares at $17.50 per share, expected to raise $250 million before expenses. The discounted issuance increases the share count and was the primary catalyst for the stock’s decline. Arcus Prices $250 Million Offering
• Negative Sentiment: Investor litigation risk: Kuehn Law said it is investigating potential fiduciary-duty violations and alleged self-dealing by company officers and directors. The announcement does not establish wrongdoing, but it adds reputational and legal uncertainty. Kuehn Law Investigation

About Arcus Biosciences

Arcus Biosciences, Inc is a clinical-stage biopharmaceutical company focused on developing therapies for cancer and other serious diseases. The company uses its research platform to discover and advance medicines designed to target immune suppression and other biological mechanisms involved in tumor growth.

Arcus’s oncology pipeline has included antibody-based and small-molecule therapies aimed at targets such as TIGIT, PD-1, CD73, and the adenosine A2A and A2B receptors. Its key development programs have included domvanalimab, zimberelimab, quemliclustat, and etrumadenant, which have been evaluated in clinical studies across several cancer types, including lung, gastrointestinal, and colorectal cancers.

Founded in 2015 and headquartered in Hayward, California, Arcus conducts research and clinical-development activities intended to support potential commercialization in international markets.